Trial · NCT04930562
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 200mg qd | 73.3 | 95% Confidence Interval 54.1 to 87.7 | percentage of participants | |
| Duration of Response (DOR) | 200mg qd | 20.2 | 95% Confidence Interval 9.71 to NA | weeks | |
| Time-to-Response (TTR) | 200mg qd | 4.29 | Full Range 3.9 to 48.1 | weeks | |
| Number of Participants With Best Response in Each Individual Organ | 200mg qd | Skin | 8 | participants | |
| Number of Participants With Best Response in Each Individual Organ | 200mg qd | Eyes | 6 | participants | |
| Number of Participants With Best Response in Each Individual Organ | 200mg qd | Mouth | 12 | participants | |
| Number of Participants With Best Response in Each Individual Organ | 200mg qd | Esophagus | 3 | participants | |
| Number of Participants With Best Response in Each Individual Organ | 200mg qd | Upper GI tract | 2 | participants | |
| Number of Participants With Best Response in Each Individual Organ | 200mg qd | Liver | 6 | participants | |
| Number of Participants With Best Response in Each Individual Organ | 200mg qd | Lungs | 2 | participants | |
| Number of Participants With Best Response in Each Individual Organ | 200mg qd | Joints and Fascia | 7 | participants | |
| Number of Participants With Change From Baseline in Overall Score on Lee cGvHD Symptom Scale at Specified Time Points | 200mg qd | Total score decline of 7 or more points from baseline | 15 | Participants | |
| Number of Participants With Change From Baseline in Overall Score on Lee cGvHD Symptom Scale at Specified Time Points | 200mg qd | Total score declined by 7 or more points from baseline on two consecutive assessments | 10 | Participants | |
| Failure-free Survival (FFS) | 200mg qd | NA | 95% Confidence Interval 7.79 to NA | months | |
| Time to Next Therapy (TTNT) | 200mg qd | NA | 95% Confidence Interval 8.9 to NA | months | |
| Overall Survival (OS) | 200mg qd | NA | 95% Confidence Interval NA to NA | months | |
| Change From Baseline in Corticosteroids Dose | 200mg qd | 0.277 | Standard Deviation 0.202 | milligrams per kilogram per day | |
| Number of Participants With Change From Baseline in Calcineurin Inhibitor (CNI) Usage. | 200mg qd | Participants with reduction in CNI dose | 7 | Participants | |
| Number of Participants With Change From Baseline in Calcineurin Inhibitor (CNI) Usage. | 200mg qd | Participants who discontinued CNI | 3 | Participants | |
| Change From Baseline in in Global Severity Rating (GSR) Score by Clinician-reported cGVHD Assessment | 200mg qd | 5.4 | Standard Deviation 1.99 | score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04930562/results